Does Immunoprecise Antibodies (USA Stocks:IPA) has enough cash to last in January?

IPA Stock  USD 4.39  0.11  2.57%   
Immunoprecise Antibodies is scheduled to announce its earnings today. As many baby boomers are still indifferent towards healthcare space, it makes sense to go over Immunoprecise Antibodies as a unique choice for millenniums. Here we also measure the ability of Immunoprecise Antibodies to meet its long-term debt obligations, such as interest payments on debt, the final principal payment on the debt, and any other fixed obligations like lease payments.
Published over a month ago
View all stories for Immunoprecise Antibodies | View All Stories
The company has 1.12 M in debt with debt to equity (D/E) ratio of 0.02, which may show that Immunoprecise Antibodies is not taking advantage of profits from borrowing. Immunoprecise Antibodies has a current ratio of 4.96, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Immunoprecise Antibodies until it has trouble settling it off, either with new capital or with free cash flow. So, Immunoprecise Antibodies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunoprecise Antibodies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunoprecise to invest in growth at high rates of return. When we think about Immunoprecise Antibodies' use of debt, we should always consider it together with cash and equity.
Immunoprecise Antibodies financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Immunoprecise Antibodies, including all of Immunoprecise Antibodies's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Immunoprecise Antibodies assets, the company is considered highly leveraged. Understanding the composition and structure of overall Immunoprecise Antibodies debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

How important is Immunoprecise Antibodies's Liquidity

Immunoprecise Antibodies financial leverage refers to using borrowed capital as a funding source to finance Immunoprecise Antibodies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunoprecise Antibodies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Immunoprecise Antibodies's total debt and its cash.

How does Immunoprecise utilize its cash?

To perform a cash flow analysis of Immunoprecise Antibodies, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Immunoprecise Antibodies is receiving and how much cash it distributes out in a given period. The Immunoprecise Antibodies cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Going after Immunoprecise Financials

The modest gains experienced by current holders of Immunoprecise Antibodies may raise some interest from investors. The stock closed today at a share price of 5.36 on 42,359 in trading volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.7. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Immunoprecise Antibodies partners.

Another small slip for Immunoprecise Antibodies

Current value at risk is at -7.45.
As of the 15th of December 2022, Immunoprecise Antibodies retains the Market Risk Adjusted Performance of 0.1106, risk adjusted performance of 0.0366, and Downside Deviation of 4.74. Immunoprecise Antibodies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Immunoprecise Antibodies, which can be compared to its competitors. Please check out Immunoprecise Antibodies maximum drawdown, and the relationship between the information ratio and downside variance to decide if Immunoprecise Antibodies is priced fairly, providing market reflects its last-minute price of 5.36 per share. Given that Immunoprecise Antibodies has jensen alpha of (0.030738), we strongly advise you to confirm Immunoprecise Antibodies's regular market performance to make sure the company can sustain itself at a future point.

The Bottom Line

Whereas other companies in the biotechnology industry are either recovering or due for a correction, Immunoprecise may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Immunoprecise valuation and our trade advice on Immunoprecise Antibodies is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Immunoprecise Antibodies.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Immunoprecise Antibodies. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to